Why Does PrEP Use Lag in Cisgender Women?
How will new study results inform HIV prevention in the US and globally? JAMA Deputy Editor Preeti Malani, MD, MSJ, and author Jeanne Marrazzo, MD, MPH, director of NIAID, discuss these study findings and more. Related Content: HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - March 1, 2024 Category: General Medicine Authors: JAMA Network Source Type: podcasts
PreP And public health
The drug Truvada, licenced for HIV PrEP, costs £350 a month but is shown to be cost effective in preventing infection. However, in the English NHS, a row has broken out about which body should fund the treatment - NHS England claims local authorities have responsibility, local authorities believe NHS England does.
In this podcast Jim McManus,... (Source: The BMJ Podcast)
Source: The BMJ Podcast - July 8, 2016 Category: Journals (General) Authors: BMJ talk medicine Source Type: podcasts
PreP And public health
The drug Truvada, licenced for HIV PrEP, costs £350 a month but is shown to be cost effective in preventing infection. However, in the English NHS, a row has broken out about which body should fund the treatment - NHS England claims local authorities have responsibility, local authorities believe NHS England does.
In this podcast Jim McManus,. .. (Source: The BMJ Podcast)
Source: The BMJ Podcast - July 8, 2016 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
PreP And public health
The drug Truvada, licenced for HIV PrEP, costs £350 a month but is shown to be cost effective in preventing infection. However, in the English NHS, a row has broken out about which body should fund the treatment - NHS England claims local authorities have responsibility, local authorities believe NHS England does.
In this podcast Jim McManus, director of public health at Hertfordshire County Council, explains why he believes local authorities cannot afford the treatment, and describes the pressure that public health budgets are under.
Read the full editorial:
http://www.bmj.com/content/354/bmj.i3515 (Source: The BMJ Podcast)
Source: The BMJ Podcast - July 8, 2016 Category: General Medicine Authors: BMJ Group Source Type: podcasts
The Tenofovir Prodrug TAF: Where Do We Stand?
Dr Paul Sax evaluates promising new clinical trial data on a coformulation of emtricitabine/elvitegravir/cobicistat with the tenofovir prodrug TAF. (Source: Medscape HIV AIDS Podcast)
Source: Medscape HIV AIDS Podcast - November 16, 2012 Category: HIV AIDS Authors: Medscape Source Type: podcasts
Top Takeaway From ICAAC 2012: More Good News on Dolutegravir
Dr. Paul Sax reviews data from the SINGLE trial presented at ICAAC 2012 on the benefits of dolutegravir/abacavir/lamivudine vs tenofovir/emtricitabine/efavirenz. (Source: Medscape HIV AIDS Podcast)
Source: Medscape HIV AIDS Podcast - October 19, 2012 Category: HIV AIDS Authors: Medscape Source Type: podcasts
